Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Referral and Consultation | 5 | 2023 | 3620 | 0.900 |
Why?
|
Oncology Service, Hospital | 2 | 2017 | 56 | 0.670 |
Why?
|
Carcinoma, Lobular | 2 | 2020 | 480 | 0.590 |
Why?
|
Abdominal Neoplasms | 1 | 2019 | 287 | 0.560 |
Why?
|
Physician Assistants | 1 | 2018 | 190 | 0.510 |
Why?
|
Breast Neoplasms | 18 | 2023 | 21206 | 0.510 |
Why?
|
Mammography | 12 | 2018 | 2433 | 0.500 |
Why?
|
Radiology | 4 | 2023 | 2104 | 0.440 |
Why?
|
Neoplasms, Second Primary | 2 | 2019 | 1061 | 0.430 |
Why?
|
Fibrocystic Breast Disease | 5 | 2000 | 103 | 0.410 |
Why?
|
Tomography, X-Ray Computed | 13 | 2023 | 20760 | 0.400 |
Why?
|
Biopsy, Needle | 8 | 2000 | 1622 | 0.360 |
Why?
|
Academic Medical Centers | 5 | 2023 | 2784 | 0.350 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 2017 | 1437 | 0.310 |
Why?
|
Breast | 8 | 2000 | 1976 | 0.300 |
Why?
|
Radiology Information Systems | 3 | 2021 | 533 | 0.290 |
Why?
|
Cancer Care Facilities | 2 | 2018 | 427 | 0.290 |
Why?
|
Inflammatory Breast Neoplasms | 2 | 2020 | 150 | 0.290 |
Why?
|
Lymphoma, T-Cell | 1 | 2009 | 308 | 0.270 |
Why?
|
Medical Oncology | 1 | 2018 | 2346 | 0.260 |
Why?
|
Liver Neoplasms | 2 | 2020 | 4362 | 0.260 |
Why?
|
Neoplasm Metastasis | 3 | 2016 | 4912 | 0.250 |
Why?
|
Evidence-Based Medicine | 1 | 2017 | 3706 | 0.240 |
Why?
|
Radiology Department, Hospital | 2 | 2019 | 409 | 0.220 |
Why?
|
Ultrasonography, Mammary | 5 | 2018 | 243 | 0.210 |
Why?
|
Magnetic Resonance Imaging | 7 | 2021 | 36743 | 0.200 |
Why?
|
Genes, erbB-2 | 2 | 2014 | 162 | 0.200 |
Why?
|
Carcinoma, Ductal, Breast | 5 | 2020 | 1099 | 0.190 |
Why?
|
Stereotaxic Techniques | 5 | 2000 | 553 | 0.190 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2020 | 2055 | 0.180 |
Why?
|
Forms and Records Control | 1 | 2020 | 158 | 0.160 |
Why?
|
Incidental Findings | 2 | 2020 | 698 | 0.150 |
Why?
|
Calcinosis | 5 | 2000 | 1481 | 0.150 |
Why?
|
Multiple Pulmonary Nodules | 1 | 2020 | 175 | 0.150 |
Why?
|
Calcium Phosphates | 1 | 2018 | 173 | 0.140 |
Why?
|
Surgical Instruments | 1 | 1999 | 381 | 0.140 |
Why?
|
Solitary Pulmonary Nodule | 1 | 2020 | 282 | 0.140 |
Why?
|
Workload | 1 | 2002 | 849 | 0.140 |
Why?
|
Environment | 1 | 2002 | 1121 | 0.130 |
Why?
|
Retrospective Studies | 18 | 2023 | 81762 | 0.130 |
Why?
|
Tumor Burden | 2 | 2014 | 1906 | 0.130 |
Why?
|
Neoplasms | 5 | 2017 | 22371 | 0.130 |
Why?
|
Lung Neoplasms | 6 | 2020 | 13586 | 0.130 |
Why?
|
Quality Improvement | 3 | 2020 | 3857 | 0.120 |
Why?
|
Foreign Bodies | 1 | 1999 | 403 | 0.120 |
Why?
|
Seat Belts | 1 | 1995 | 60 | 0.120 |
Why?
|
Immunoconjugates | 1 | 2023 | 975 | 0.120 |
Why?
|
Humans | 50 | 2023 | 768166 | 0.120 |
Why?
|
Patient Care Planning | 1 | 2020 | 905 | 0.120 |
Why?
|
Positron-Emission Tomography | 4 | 2017 | 6669 | 0.110 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2017 | 9419 | 0.110 |
Why?
|
Receptors, Progesterone | 2 | 2020 | 1160 | 0.110 |
Why?
|
Female | 37 | 2023 | 397192 | 0.100 |
Why?
|
Terminology as Topic | 1 | 2020 | 1542 | 0.100 |
Why?
|
Clinical Protocols | 1 | 2018 | 1443 | 0.100 |
Why?
|
Radiopharmaceuticals | 2 | 2020 | 2735 | 0.100 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 1999 | 934 | 0.100 |
Why?
|
Receptor, erbB-2 | 3 | 2023 | 2603 | 0.090 |
Why?
|
Receptors, Estrogen | 2 | 2020 | 2253 | 0.090 |
Why?
|
Genes, BRCA1 | 1 | 2014 | 755 | 0.090 |
Why?
|
Interprofessional Relations | 1 | 2017 | 997 | 0.090 |
Why?
|
Mucous Membrane | 1 | 2013 | 659 | 0.090 |
Why?
|
Quinazolines | 2 | 2014 | 1373 | 0.090 |
Why?
|
Breast Diseases | 3 | 1998 | 442 | 0.090 |
Why?
|
Immunoblastic Lymphadenopathy | 1 | 2009 | 40 | 0.080 |
Why?
|
Pleural Neoplasms | 1 | 2014 | 612 | 0.080 |
Why?
|
Prognosis | 4 | 2019 | 30010 | 0.080 |
Why?
|
Accidents, Traffic | 1 | 1995 | 818 | 0.080 |
Why?
|
Survival Analysis | 2 | 2019 | 10101 | 0.080 |
Why?
|
Contrast Media | 3 | 2018 | 5330 | 0.080 |
Why?
|
Leukemia-Lymphoma, Adult T-Cell | 1 | 2009 | 168 | 0.080 |
Why?
|
Neoplasm Staging | 7 | 2020 | 11244 | 0.070 |
Why?
|
Pulmonary Embolism | 2 | 2012 | 2599 | 0.070 |
Why?
|
Middle Aged | 25 | 2020 | 223492 | 0.070 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2016 | 951 | 0.070 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 2009 | 168 | 0.070 |
Why?
|
Aged | 21 | 2020 | 171504 | 0.070 |
Why?
|
Nose Neoplasms | 1 | 2009 | 250 | 0.070 |
Why?
|
Follow-Up Studies | 6 | 2020 | 39348 | 0.070 |
Why?
|
Decision Support Techniques | 1 | 2017 | 2008 | 0.070 |
Why?
|
Hodgkin Disease | 1 | 2014 | 1384 | 0.070 |
Why?
|
Patient-Centered Care | 1 | 2017 | 1444 | 0.070 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2010 | 459 | 0.070 |
Why?
|
Central Nervous System Neoplasms | 1 | 2014 | 928 | 0.060 |
Why?
|
Adult | 21 | 2020 | 223646 | 0.060 |
Why?
|
Molecular Targeted Therapy | 1 | 2017 | 2830 | 0.060 |
Why?
|
Melanoma | 2 | 2014 | 5706 | 0.060 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 1999 | 3447 | 0.060 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2016 | 2043 | 0.060 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2014 | 5432 | 0.060 |
Why?
|
Carcinoma in Situ | 2 | 2000 | 788 | 0.050 |
Why?
|
Aged, 80 and over | 9 | 2019 | 59629 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2014 | 11878 | 0.050 |
Why?
|
Radiation Injuries | 1 | 2010 | 1198 | 0.050 |
Why?
|
Boston | 3 | 2019 | 9374 | 0.050 |
Why?
|
Brachytherapy | 1 | 2010 | 1220 | 0.050 |
Why?
|
Physicians | 1 | 2020 | 4598 | 0.050 |
Why?
|
Mass Screening | 1 | 2018 | 5458 | 0.050 |
Why?
|
Bone Neoplasms | 1 | 2014 | 2565 | 0.050 |
Why?
|
Iohexol | 2 | 2014 | 205 | 0.050 |
Why?
|
Radiography | 2 | 2023 | 6983 | 0.050 |
Why?
|
Brain Neoplasms | 1 | 2023 | 9118 | 0.050 |
Why?
|
Diagnosis, Differential | 3 | 2020 | 13014 | 0.050 |
Why?
|
Camptothecin | 1 | 2023 | 600 | 0.040 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2005 | 617 | 0.040 |
Why?
|
Antineoplastic Agents | 3 | 2017 | 13676 | 0.040 |
Why?
|
Medical Record Linkage | 1 | 2019 | 286 | 0.040 |
Why?
|
Radiographic Image Enhancement | 2 | 2014 | 877 | 0.040 |
Why?
|
Workflow | 1 | 2022 | 860 | 0.040 |
Why?
|
Treatment Outcome | 7 | 2023 | 65371 | 0.040 |
Why?
|
Ultrasonography, Interventional | 2 | 2002 | 1523 | 0.030 |
Why?
|
Negotiating | 1 | 2018 | 152 | 0.030 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2012 | 4058 | 0.030 |
Why?
|
Radiographic Magnification | 1 | 1996 | 18 | 0.030 |
Why?
|
Male | 11 | 2017 | 364719 | 0.030 |
Why?
|
Fibroadenoma | 1 | 1996 | 42 | 0.030 |
Why?
|
Axilla | 1 | 2018 | 623 | 0.030 |
Why?
|
Comprehensive Health Care | 1 | 2016 | 123 | 0.030 |
Why?
|
Fat Necrosis | 1 | 1995 | 60 | 0.030 |
Why?
|
Adenocarcinoma | 1 | 2012 | 6395 | 0.030 |
Why?
|
Contusions | 1 | 1995 | 78 | 0.030 |
Why?
|
Risk | 2 | 2018 | 9613 | 0.030 |
Why?
|
Piperazines | 1 | 2005 | 2554 | 0.030 |
Why?
|
Radiography, Interventional | 2 | 1999 | 1131 | 0.030 |
Why?
|
Evaluation Studies as Topic | 1 | 1996 | 1627 | 0.030 |
Why?
|
Data Collection | 1 | 2002 | 3327 | 0.030 |
Why?
|
Pyrimidines | 1 | 2005 | 3048 | 0.030 |
Why?
|
Antibodies, Neoplasm | 1 | 2014 | 283 | 0.030 |
Why?
|
Lymph Node Excision | 1 | 2018 | 1271 | 0.030 |
Why?
|
Models, Organizational | 1 | 2016 | 548 | 0.030 |
Why?
|
Cysts | 1 | 1997 | 685 | 0.020 |
Why?
|
Vinblastine | 1 | 2013 | 487 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 2 | 2012 | 6526 | 0.020 |
Why?
|
Markov Chains | 1 | 2014 | 979 | 0.020 |
Why?
|
Maytansine | 1 | 2011 | 88 | 0.020 |
Why?
|
Mastectomy, Segmental | 1 | 1996 | 974 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 1 | 1996 | 1791 | 0.020 |
Why?
|
Biopsy | 2 | 1999 | 6793 | 0.020 |
Why?
|
Mastectomy | 1 | 2018 | 1861 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2018 | 3556 | 0.020 |
Why?
|
Ultrasonography | 2 | 2000 | 6004 | 0.020 |
Why?
|
Estrogen Replacement Therapy | 1 | 1996 | 1209 | 0.020 |
Why?
|
Skin Neoplasms | 1 | 2009 | 5863 | 0.020 |
Why?
|
Vacuum | 2 | 2000 | 65 | 0.020 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2014 | 1105 | 0.020 |
Why?
|
Life Expectancy | 1 | 2014 | 1248 | 0.020 |
Why?
|
Risk Factors | 1 | 2014 | 74944 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2018 | 2907 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2012 | 2862 | 0.020 |
Why?
|
Prospective Studies | 2 | 2023 | 54926 | 0.020 |
Why?
|
Angiogenesis Inhibitors | 1 | 2017 | 2056 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2014 | 4860 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2013 | 2914 | 0.020 |
Why?
|
Radiation Dosage | 1 | 2014 | 1967 | 0.020 |
Why?
|
Massachusetts | 1 | 2018 | 8890 | 0.020 |
Why?
|
Cohort Studies | 2 | 2023 | 41754 | 0.020 |
Why?
|
Decision Making | 1 | 2018 | 3953 | 0.010 |
Why?
|
Observer Variation | 1 | 2010 | 2622 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2014 | 2631 | 0.010 |
Why?
|
Survivors | 1 | 2014 | 2381 | 0.010 |
Why?
|
Time Factors | 2 | 1996 | 40218 | 0.010 |
Why?
|
Outpatients | 1 | 2011 | 1600 | 0.010 |
Why?
|
Lymph Nodes | 1 | 1993 | 3474 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2014 | 10760 | 0.010 |
Why?
|
Diagnostic Imaging | 1 | 2016 | 3533 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2002 | 26379 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2014 | 5536 | 0.010 |
Why?
|
Sex Factors | 1 | 2014 | 10632 | 0.010 |
Why?
|
Biomedical Research | 1 | 2016 | 3463 | 0.010 |
Why?
|
Recurrence | 1 | 2012 | 8509 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2014 | 3239 | 0.010 |
Why?
|
Benzamides | 1 | 2005 | 1379 | 0.010 |
Why?
|
Venous Thromboembolism | 1 | 2012 | 1883 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12077 | 0.010 |
Why?
|
Automation | 1 | 2000 | 589 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2014 | 5703 | 0.010 |
Why?
|
Age Factors | 1 | 2014 | 18412 | 0.010 |
Why?
|
Smoking | 1 | 2014 | 9092 | 0.010 |
Why?
|
Hyperplasia | 1 | 2000 | 1151 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2014 | 9015 | 0.010 |
Why?
|
Imaging, Three-Dimensional | 1 | 2010 | 4063 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2014 | 9263 | 0.010 |
Why?
|
Anticoagulants | 1 | 2012 | 4852 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2014 | 20227 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2000 | 3436 | 0.010 |
Why?
|
Equipment Design | 1 | 2000 | 3522 | 0.010 |
Why?
|
Incidence | 1 | 2011 | 21538 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 2000 | 3620 | 0.010 |
Why?
|
Lung | 1 | 2010 | 10099 | 0.010 |
Why?
|
Young Adult | 1 | 2011 | 60066 | 0.000 |
Why?
|
Case-Control Studies | 1 | 1997 | 22291 | 0.000 |
Why?
|
Adolescent | 1 | 2005 | 89169 | 0.000 |
Why?
|